Patent Application
20230098220
The present invention is generally directed to a cardiac rhythm management system (CRMS) that can be used for electric stimulation therapy of cardiac arrhythmia. Such a cardiac rhythm management system comprises at least one first implantable stimulation device, for example, an implantable leadless pacemaker (ILP), and at least one second implantable stimulation device, for example, a subcutaneous implantable cardioverter defibrillator (S-ICD) or an ILP, wherein the at least one first implantable stimulation device comprises a first detection unit adapted to detect a patient's cardiac rhythm and a first processor adapted to analyze the detected patient's cardiac rhythm and to deliver signals for a first antitachycardia pacing therapy, wherein the at least one second implantable stimulation device comprises a second detection unit adapted to detect the patient's cardiac rhythm and a second processor adapted to analyze the detected patient's cardiac rhythm and to deliver signals for shock therapy or a second antitachycardia pacing therapy.
Implantable stimulation devices such as implantable cardiac pacemakers or ILPs are well known medical devices that allow stimulation of the heart of a patient. In general, those medical devices are battery operated and a stimulation component is directly implanted into the heart's ventricle or atrium. Implantable cardiac pacemakers have at least an elongated stimulation lead which reaches from the device housing into a heart chamber where it is anchored. ILPs are miniaturized pacing devices which are entirely implanted into the heart chamber.
Implantable stimulation devices with a defibrillation function are known in the art, as for instance implantable cardioverter-defibrillators (ICD) or subcutaneous implantable cardioverter-defibrillators (SICD). Such devices typically comprise of a device housing and at least one elongated stimulation lead which extends from the housing. The housing of an ICD is typically implanted in a skin pocket below the clavicle, wherein the stimulation lead reaches into the ventricle of the heart where it is fixed. The housing and stimulation lead of an SICD are implanted under the skin (i.e., subcutaneously), in a way that a shock vector that runs through the cardiac ventricles is created between the stimulation electrode(s) of the lead and the SICD housing.
The medical device is chosen according to the patient's cardiac condition, i.e., the required cardiac therapy.
Implantable pacemakers or ILPs are used for patients who suffer from a bradycardia, that is if a heart that beats too slow to fulfil the physiological needs of the patient. The implantable pacemaker or ILP applies electrical stimulation to the heart in order to generate a physiologically appropriate heartrate.
ICDs are used for patients who suffer from ventricular tachycardia and fibrillations. The ICD is able to apply antitachycardia pacing (ATP) therapy (i.e., pacing the heart with a faster stimulation rate than the tachycardia rate) to terminate a tachycardia, or a shock therapy (i.e., high energetic electric shock which is applied to the ventricles to terminate the tachycardia to bring back the heart to a physiological rhythm) if the tachycardia persists after ATP attempts.
SICDs are configured to deliver a shock therapy, but no pacing therapy or ATP therapy. That is due to the distance between stimulation lead and the cardiac chambers, so that a low energetic stimulation pulse could not be delivered effectively to a cardiac pacing site.
An ILP may deliver pacing therapy and ATP, but no shock therapy. Due to the highly restricted device size, it has a small battery capacity and lack of space for charging capacitors required for providing a shock therapy.
Moreover, implantable leads pose a risk to the patient and can therefore be a problem. The lead is an elongated insulated electrode wire which reaches from the device housing into the venous system of the heart where it is anchored in the ventricle. It undergoes different forces and movements with every beat of the heart, which can result in lead dislodgement, insulation failures and lead breach. That problem does not occur with SICDs and ILPs, because these devices have no intracardiac elongated lead. Especially for patients who have no adequate vascular access or are at high risk for infection, no elongated leads can be implanted inside the heart.
However, there are circumstances in which a patient suffers from various cardiac arrhythmias that require different cardiac therapies. In such cases, a CRMS may be implanted comprising at least two medical devices or units.
Furthermore, there exist cardiac arrhythmias for which different therapies are suitable and one treatment is more favorable, e.g., more comfortable, for the patient. Further, some therapies may cause another arrhythmia, so that an additional therapy is required in order to stop this arrhythmia. In practice, ventricular tachycardia, for example, may be treated using ATP therapy or shock therapy, wherein shock therapy is often uncomfortable for patients as the shocks are emitted unexpectedly and may be painful. In addition, shock therapies cause a considerable decrease in the longevity of the battery. Nevertheless, shock therapy is inevitable if a ventricular tachycardia leads to ventricular fibrillation as ATP therapy is not suitable to treat fibrillations.
For instance, a patient who has a contraindication for intracardiac elongated leads and who suffers from ventricular tachycardia requires pacing therapy, ATP and shock therapy. In such case, a CRMS may be implanted comprising at least a first implantable stimulation device and a second implantable stimulation device, wherein the first implantable stimulation device may be an ILP, and the second device an SICD.
According to another example, if a patient who has a contraindication for intracardiac elongated leads and who requires pacing therapy and/or ATP, in the ventricle (or at the HIS bundle) and in the atrium, a CRMS may be implanted comprising at least a first implantable stimulation device and a second implantable stimulation device, wherein the first implantable stimulation device may be a first ILP, and the second device a second ILP.
Cardiac rhythm management systems comprising multiple treatment therapies are, for example, provided by a combination of S-ICD and ILP as disclosed in the prior art documents U.S. Publication No. 2019/0160285 A1 and U.S. Pat. No. 10,265,534 B2. The coordination of such systems is obligatory in order to provide proper treatment as the therapies may be ineffective if they are applied simultaneously.
Therefore, the system described in document U.S. Publication No. 2019/0160285 A1 discloses the use of multiple medical devices that allow the delivery of stimulation therapy for cardiac arrhythmia, wherein a communication between the medical devices of the system is mentioned in order to provide the required coordination. Document U.S. Pat. No. 10,265,534 B2 discloses a further communication method for a system with a leadless first implantable stimulation device and another implanted device comprising the exchange of communication messages.
However, an external or internal communication within a CRMS, i.e., between one implanted medical device and an external device or between two implanted medical devices, has some disadvantages. These disadvantages are mainly due to the fact that the communication requires communication interfaces, which in turn cause increased energy consumption. In addition, the communication interfaces are vulnerable for cyber-attacks. Furthermore, an undisturbed communication channel is required in order to provide a reliably functioning of a CRMS.
The present disclosure is directed toward overcoming one or more of the above-mentioned problems, though not necessarily limited to embodiments that do.
Therefore, it is an object of the present invention to provide a cardiac rhythm management system and a respective method, which benefits from the combined use of a first implantable stimulation device and a second implantable stimulation device providing combined therapy and which is synchronized without using any separate communication channel. Further, it is an object of the present invention to provide a reliable functioning CRMS, which is user-friendly.
At least this problem is solved by a cardiac rhythm management system with the features of claim 1, as well as with a cardiac rhythm management method for a cardiac rhythm management system with the features of claim 11.
In particular, a cardiac rhythm management system according to the present invention is disclosed comprising at least one first implantable stimulation device, for example, an ILP, and at least one second implantable stimulation device, for example, a subcutaneous implantable cardioverter defibrillator or an ILP. Both medical devices, i.e., pacing and second implantable stimulation devices, may be implanted in the chest cavity. More precise, the first implantable stimulation device may be implanted in one heart ventricle or atrium and the second implantable stimulation device may be implanted outside the heart. Further, the at least one first implantable stimulation device comprises a first detection unit, e.g., comprising one or more electrodes adapted to be implanted into the heart's tissue, adapted to detect a patient's cardiac rhythm and a first processor adapted to analyze the detected patient's cardiac rhythm and to deliver signals for a first antitachycardia pacing (ATP) therapy. The first implantable stimulation device with the first detection unit and the first processor may be formed as an integral structure.
Furthermore, the at least one second implantable stimulation device comprises a second detection unit adapted to detect the patient's cardiac rhythm and a second processor adapted to analyze the detected patient's cardiac rhythm and to deliver signals for shock therapy or a second antitachycardia pacing (ATP) therapy.
In case that the second implantable stimulation device is a S-ICD, the second detection unit may comprise at least one detection electrode to detect the patient's cardiac rhythm and the second processor may be electrically connected to at least one shock coil and/or a pulse generator via an electrode lead. The electrode lead may be fixed to the pulse generator or may be connected via a connector pin. Further, the S-ICD may be implanted completely subcutaneous, wherein the components are positioned around the heart but not within the heart. The shock coil and a housing of the S-ICD are accommodated such that an electric shock wave produced by the shock coil is transmitted via at least one heart ventricle to the electrically conducting housing of the S-ICD. As there are no components of the S-ICD directly inserted into the heart, the advantages of an S-ICD are consequently a less irritation of the heart, a lower risk of infection and less mechanical stress of the components. The S-ICD may be placed according to anatomical guidance and does not require any imaging systems such as an X-ray imaging system. The electrode lead of the S-ICD may be inserted parallel to the sternum and the housing with the pulse generator and the second processor may be placed at the left chest wall.
According to this embodiment, the first processor of the first implantable stimulation device is adapted to allow delivery of signals for ATP therapy only if the analysis of the patient's cardiac rhythm within a pre-defined preceding time period A reveals a pre-defined tachycardia criterion A′ and an absence of a shock therapy, and/or the second processor of the second implantable stimulation device is adapted to allow delivery of signals for shock therapy or a second ATP therapy only if the analysis of the patient's cardiac rhythm within a pre-defined preceding time period B reveals a pre-defined tachycardia criterion B′ and an absence of a first antitachycardia pacing therapy provided by the at least one first implantable stimulation device.
Thus, an ATP therapy triggered by the signals produced by the first processor is only allowed to be delivered by the first implantable stimulation device if the above conditions are satisfied. The ATP therapy is triggered by the respective signals of the first processor and provided by a respective first signal generator of the first implantable stimulation device which is connected to the first processor and produces the signals which are to be sent by a subset of at least two electrodes to the heart of the patient. Alternatively or additionally, an ATP therapy or shock therapy triggered by the respective signals produced by the second processor is only allowed to be delivered by the second implantable stimulation device if the above conditions are satisfied. The ATP therapy is provided by a respective signal generator of the second implantable stimulation device which is connected to the second processor and produces signals to be sent by a subset of at least two electrodes connected to the housing of the second implantable stimulation device to the heart of the patient. The shock therapy may be provided by a shock unit of the second implantable stimulation device which is connected to the second processor and produces at least one shock signal via at least one shock coil connected by a lead to the housing of the second implantable stimulation device.
The existence of a pre-defined tachycardia criterion A′ or second tachycardia criterion may be revealed if, for example, a pre-defined heart rate or QRS duration is exceeded by the detected cardiac rhythm of the patient is within the time period A or the time period B. Therefore, the first and second processors may be adapted to analyze the detected patient's cardiac rhythm, wherein the detected patient's cardiac rhythm may be realized by a sensed electrocardiogram (ECG). For example, the pre-defined heart rate up to which an ATP-therapy is delivered may be 120 to 180 bpm (beats per minute), in particular 160 bpm. This criterion may be part of the tachycardia criterion A′.
The time period A or the time period B may be regarded as, for example, 10 to 60 seconds, 1, 2, 3 to 5 minutes, in particular 60 seconds in the past from the actual/most recent time point. Time period A and time period B may be different in length, for example, the time period A is longer than the time period B.
Moreover, the ATP-therapy delivered by a respective impulse generator of the first implantable stimulation device and/or the second implantable stimulation device may comprise pattern elements, for example, least one burst and/or at least one ramp and/or at least one burst with an extra stimulus, wherein preferably the number of pattern elements is at least 8.
Additionally, the existence or absence of the shock therapy provided by the defibrillator device may be revealed by first processor by the analysis of the detected patient's cardiac rhythm, as well, wherein the detected patient's cardiac rhythm may be given by a sensed ECG. For instance, the detection of an applied shock therapy will be based on the detection of the high voltage applied and optional based on the detection of the typical shock waveform (e.g., biphasic). The decision whether a shock is applied is made by the first processor, for example, by a detailed analysis of the ECG signals with regard to the peak height, the peak width and the peak distribution over time. If in the ECG no shock signal is detected within the time period A, the result of the first processor's analysis of the ECG signal is that no shock therapy was provided by the defibrillator device during the time period A.
Further, the existence or absence of the ATP therapy provided by the first implantable stimulation device may be revealed by second processor by the analysis of the detected patient's cardiac rhythm, as well, wherein the detected patient's cardiac rhythm may be given by a sensed ECG. For instance, the detection of an ATP delivery could be based on the recognition of the typical ATP pattern (5-10 pacing pulses with a constant interval [Burst] or a decreasing interval length for per inter-pulse interval [Ramp]). The decision whether a shock is applied is made by the second processor, for example, by a detailed analysis of the ECG signals with regard to the peak height, the peak width and the peak distribution over time. If in the ECG no ATP therapy signal is detected within the time period B, the result of the second processor's analysis of the ECG signal is that no ATP therapy was provided by the first implantable stimulation device during the time period B.
The above inventive solution shows that the first implantable stimulation device and the second implantable stimulation device of the CRMS use the electrical signals of the respective other device in order to detect whether there was a therapy provided by the other device within a respective pre-defined time period prior the actual/recent time point. Additional communication of the devices, for example, using radio waves or other communication channels is not necessary. Accordingly, no additional communication unit/interfaces or energy consumption for separate communication or keeping a communication unit active is necessary. The coordination/management of the therapy of the at least two devices works by using the electrical signals produced by the respective patient or of an implanted device for the therapy of the same patient. Relevant electrical signals are for instance pacing pulses (amplitudes between 0.2 to 10V, pulse width 0.1 to 1.5 ms), and defibrillations shocks (monophasic or biphasic waveform; 100 to 1400V; pulse duration 4 to 80 ms). Further, the usage of the inventive CRMS is user friendly as well as simple and cost-effective in its structure.
In one embodiment, the first processor is adapted to prevent delivery of signals for ATP therapy for a time period C if the analysis of the patient's cardiac rhythm within the time period A reveals delivery of a shock therapy. In one embodiment, the prevention of the delivery of signals for ATP therapy may be permanently or until an operator re-activates the delivery of signals for ATP therapy. Thus, the time period C may last until a check of the CRMS is performed and, as a result of this, the time period C is terminated by an operator. Additionally, the time period C may be terminated if a pre-defined criterion is detected that reveals the termination of an arrhythmia. Alternatively, the time period C may have a certain, pre-defined length of 3 to 5, 6 to 10, 10 to 15, 15 to 20, 20 to 25, 25 to 30, 30 to 40, 40 to 50, 50 to 60 seconds, or 1 to 1.5, 1.5 to 2, 2 to 2.5, 2.5 to 3, 3 to 5 minutes, 5 to 60 minutes, to multiple hours. If, after revealing of delivery of a shock therapy, the first processor would not be adapted to prevent delivery of signals for ATP-therapy for a time period C, the ATP- and shock therapy could be applied simultaneously or within a close timely proximity. However, a simultaneous application of ATP- and shock therapy may influence the effectiveness of either one of the therapies. More importantly, a simultaneous application of both therapies may even harm the patient as the point in time, in which a shock should be applied to be effective, may be missed as the patient's cardiac rhythm is often changed caused by the application of ATP therapy.
In one embodiment, the second processor is adapted to prevent delivery of signals for shock therapy or a second ATP therapy for a time period D if the analysis of the patient's cardiac rhythm within the time period B reveals delivery of a first ATP therapy. In one embodiment, the prevention of the delivery of signals for shock therapy or the second ATP-therapy may be permanently or until an operator re-activates the delivery of signals for shock therapy or second ATP therapy. Thus, the time period D may last until a check of the CRMS is performed and, as a result of this, the time period D is terminated by an operator. Additionally, the time period D may be terminated if a pre-defined criterion is detected that reveals the termination of an arrhythmia. Alternatively, the time period D may have a certain, pre-defined length of 3 to 5, 6 to 10, 10 to 15, 15 to 20, 20 to 25, 25 to 30, 30 to 40, 40 to 50, 50 to 60 seconds, or 1 to 1.5, 1.5 to 2, 2 to 2.5, 2.5 to 3, 3 to 5 minutes, 5 to 60 minutes, to multiple hours. If, after revealing of delivery of a first ATP therapy, the second processor would not be adapted to prevent delivery of signals for shock therapy or second ATP therapy for a time period D the second ATP therapy or shock therapy may be applied simultaneously with the first ATP therapy or in close timely proximity. As indicated above, a simultaneous application of ATP and shock therapy may influence the effectiveness of either one of the therapies or may harm the patient.
The time period D may last as long as a time period needed for the application of the first ATP therapy. In order to apply shock therapy promptly after ATP therapy, it can be advantageous if the second implantable stimulation device starts loading for the at least one shock during ATP therapy. A more battery-saving variant of this premature start of charging, includes, in particular, a continuous analysis of the detected patient's cardiac rhythm, so that the start of loading for the shock begins when an ongoing arrhythmia following the first ATP therapy seems likely.
In one embodiment, the second processor is adapted to allow delivery of signals for shock therapy if the patient's cardiac rhythm within the time period B reveals a heart rate above a pre-defined limit. In this case, an immediate application of shock therapy may be needed in order to help the patient. Moreover, a shock may be delivered based on the parameters (alone or in combination) of a pathologic QRS waveform, a pathologic ECG signal pattern (e.g., over 10-20 sec), sudden rate increase, and/or rate stability/instability.
In one embodiment the first processor is adapted to re-analyze the patient's cardiac rhythm according to the pre-defined tachycardia criterion A′ during the time period C and/or the second processor is adapted to re-analyze the patient's cardiac rhythm according to the pre-defined tachycardia criterion B′ during the time period D. This means that if a shock therapy or an ATP therapy occurred a re-analysis of the patient's cardiac rhythm is provided, namely, during the time period C or the time period D. In this embodiment, the re-analysis of the patient's cardiac rhythm is provided in the same way as during initial detection of a tachycardia, namely, using the predefined tachycardia criterion A′ or the predefined tachycardia criterion B′. For instance, time period C or time period D may have a length of 5 to 120 seconds.
In another embodiment, during the time period C or the time period B different predefined tachycardia criteria are used for the analysis of the patient's cardiac rhythm. In this embodiment, the first processor is adapted to re-analyze the patient's cardiac rhythm according to a pre-defined tachycardia criterion C′ during the time period C and/or the second processor is adapted to re-analyze the patient's cardiac rhythm according to a pre-defined tachycardia criterion D′ during the time period D, wherein the pre-defined tachycardia criterion C′ is different from the pre-defined tachycardia criterion A′ and the pre-defined tachycardia criterion D′ is different from the pre-defined tachycardia criterion B′.
The existence of a pre-defined tachycardia criterion C′ or tachycardia criterion D′ may be revealed if, for example, a pre-defined heart rate or QRS duration is exceeded by the detected cardiac rhythm of the patient is within the time period C or the time period D. A pre-defined heart rate is, for example, a heart rate 120 to 220 bpm. Therefore, the first and second processors may be adapted to analyze the detected patient's cardiac rhythm, wherein the detected patient's cardiac rhythm may be realized by a sensed electrocardiogram (ECG).
In one embodiment, the first processor and/or the second processor are/is adapted to terminate the time period C and/or the time period D upon receipt of a termination signal. This termination signal may be provided by an operator or a program routine, for example, via a communication to an external device. For example, if the delivery of an ATP therapy is detected during a loading time period of a shock unit for shock delivery a re-evaluation of the patient's cardiac rhythm is provided during a short confirmation detection phase.
As the delivery of at least one shock during shock therapy by the second implantable stimulation device needs a high voltage the shock therapy comprises a loading/charging time period prior the at least one shock is applied by the shock unit to the patient. This loading time period is needed in order to charge at least one capacitor or another capacitive element of the shock unit.
Even if, in one embodiment, the shock therapy is started by loading/charging at least one capacitor of the shock unit, in this embodiment the application of the at least one shock by the shock unit is prevented if the patient's cardiac rhythm within a time period E during or after the loading time period does not correspond to a pre-defined tachycardia criterion E′, wherein the pre-defined tachycardia criterion E′ may be different from any one or several of the tachycardia criteria A′-D′. Time period E may be for instance 1 to 10 seconds after charging. The charging process typically takes 1 to 24 seconds. The existence of a pre-defined tachycardia criterion E′ may be revealed if, for example, a pre-defined heart rate or QRS duration is exceeded by the detected cardiac rhythm of the patient is within the time period E. Therefore, the first and second processors may be adapted to analyze the detected patient's cardiac rhythm, wherein the detected patient's cardiac rhythm may be realized by a sensed electrocardiogram (ECG). Such pre-defined tachycardia criterion E′ may comprise the heart rate. If the detected heart rate is below a predefined heart rate, for example, the application of at least one shock is not necessary. This may reduce the stress for the patient. Pre-defined tachycardia criteria E′ may be (alone or in combination) a heart rate from 120 to 220 bpm, pathologic QRS waveform, pathologic ECG signal pattern (e.g., over 10 to 20 sec), sudden rate increase, rate stability/instability.
In one embodiment, the first processor of the first implantable stimulation device is adapted to deliver signals for at least one other cardiac therapy such as bradycardia pacing therapy or cardiac stimulation for blood pressure reduction.
In stimulation for blood pressure reduction, the timing for stimulating the atrium is performed slightly non-synchronically with respect to a physiologically effective cardiac cycle. As a result, a reduction of the patient's blood pressure is achieved.
At least the above problem is also solved by a cardiac rhythm management method for a cardiac rhythm management system, comprising:
at least one first implantable stimulation device, for example, an ILP, and
at least one second implantable stimulation device, for example, a subcutaneous implantable cardioverter defibrillator or an ILP,
wherein a first detection unit of the at least one first implantable stimulation device detects a patient's cardiac rhythm and a first processor of the at least one first implantable stimulation device analyzes the detected patient's cardiac rhythm,
wherein a second detection unit of the at least one second implantable stimulation device detects the patient's cardiac rhythm and a second processor of the at least one second implantable stimulation device analyzes the detected patient's cardiac rhythm, and
wherein the first processor delivers signals for a first antitachycardia pacing therapy only if the analysis of the patient's cardiac rhythm within a pre-defined preceding time period A reveals a pre-defined tachycardia criterion A′ and an absence of a shock therapy, and/or
wherein the second processor delivers of signals for shock therapy or a second antitachycardia pacing therapy only if the analysis of the patient's cardiac rhythm within a pre-defined preceding time period B reveals a pre-defined tachycardia criterion B′ and an absence of a first antitachycardia pacing therapy. This method provides the same advantages as the above described system.
Further, the above mentioned limitations and further explanations of the system do also apply to the embodiments of the system defined above and described below.
According to one embodiment of the cardiac rhythm management method, the first processor prevents delivery of signals for antitachycardia pacing therapy for a time period C if the analysis of the patient's cardiac rhythm within the time period A reveals delivery of a shock therapy.
According to one embodiment, the second processor prevents delivery of signals for shock therapy for a time period D if the analysis of the patient's cardiac rhythm within the time period B reveals delivery of a first antitachycardia pacing therapy.
According to one embodiment of the method, the second processor delivers of signals for shock therapy or a second antitachycardia pacing therapy if the patient's cardiac rhythm within the time period B reveals a heart rate above a preset limit.
According to one embodiment of the method, the first processor re-analyzes the patient's cardiac rhythm according to the pre-defined tachycardia criterion A′ during the time period C and/or the second processor re-analyzes the patient's cardiac rhythm according to the pre-defined tachycardia criterion B′ during the time period D.
According to one embodiment of the method, the first processor re-analyzes the patient's cardiac rhythm according to a pre-defined tachycardia criterion C′ during the time period C and/or the second processor re-analyzes the patient's cardiac rhythm according to a pre-defined tachycardia criterion D′ during the time period D, wherein the pre-defined tachycardia criterion C′ is different from the pre-defined tachycardia criterion A′ and the pre-defined tachycardia criterion D′ is different from the pre-defined tachycardia criterion B′.
According to one embodiment of the method, the first and/or second processor terminates the time period C and/or the time period D upon receipt of a termination signal.
According to one embodiment, the delivery of at least one shock during the shock therapy by a shock unit of the second implantable stimulation device comprises waiting for a loading time period prior the at least one shock is applied by the shock unit to the patient.
In this embodiment, the shock unit does not deliver the at least one shock if the patient's cardiac rhythm within a time period E during or after the loading time period does not correspond to a pre-defined tachycardia criterion E′.
According to an embodiment, the first processor of the first implantable stimulation device delivers signals for at least one other cardiac therapy such as bradycardia therapy or stimulation for blood pressure reduction.
Additional features, aspects, objects, advantages, and possible applications of the present disclosure will become apparent from a study of the exemplary embodiments and examples described below, in combination with the Figures and the appended claims.
The present invention will now be described in further detail with reference to the accompanying schematic drawings, wherein:
The ILP 30 comprises one or more electrodes as a first detection unit for sensing electric signals of the heart H. Further, the one more electrodes may be used for application antitachycardia pacing (ATP) therapy or other cardiac therapy. The detected electric signals are transmitted to a first processor accommodated within the ILP 30. The first processor analyzes the electric signals of the heart (e.g., ECG signals) and thereby determines the patient's cardiac rhythm which may comprise, as shown in
The S-ICD 1 comprises within its housing 10 a second processor and a shock unit. The lead 2 is implanted subcutaneous along the sternum 20 and comprises two detection electrodes 200, 203 as a second detection unit and a shock coil 202 for application of a cardioversion or defibrillation shock. The detection electrodes 200, 203 detect electric signals of and around the heart H and transmit these signals to the second processor accommodated within the housing 10. The second processor analyzes the electric signals of the heart (e.g., the ECG signals) and thereby determines the patient's cardiac rhythm which may comprise, as shown in
The flow chart of
Analog to the flow chart of
Further, as indicated in
The above system and method provide a modular cardiac rhythm management of two devices providing antitachycardia therapy implanted in the same patient without the necessity of providing any separate communication channel. The system and method just use the analysis of the patient's cardia rhythm provided anyway for co-ordination of the operation of each device. Accordingly, the system is cost-effective and power-saving as well as reliable and user-friendly. The inventive system and method avoids cyber-attacks.
It will be apparent to those skilled in the art that numerous modifications and variations of the described examples and embodiments are possible in light of the above teachings of the disclosure. The disclosed examples and embodiments are presented for purposes of illustration only. Other alternate embodiments may include some or all of the features disclosed herein. Therefore, it is the intent to cover all such modifications and alternate embodiments as may come within the true scope of this invention, which is to be given the full breadth thereof. Additionally, the disclosure of a range of values is a disclosure of every numerical value within that range, including the end points.
| Number | Date | Country | Kind |
|---|---|---|---|
| 20178714.0 | Jun 2020 | EP | regional |
This application is the United States National Phase under 35 U.S.C. § 371 of PCT International Patent Application No. PCT/EP2021/057080, filed on Mar. 19, 2021, which claims the benefit of European Patent Application No. 20178714.0, filed on Jun. 8, 2020, and U.S. Provisional Patent Application No. 62/993,083, filed on Mar. 23, 2020, the disclosures of which are hereby incorporated by reference herein in their entireties.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/EP2021/057080 | 3/19/2021 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 62993083 | Mar 2020 | US |
